57
Participants
Start Date
October 4, 2021
Primary Completion Date
September 19, 2024
Study Completion Date
September 19, 2024
INCA00186
INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
Retifanlimab
Retifanlimab will be administered every 4 weeks as per protocol
INCB106385
INCB106385 will be administered orally once or twice a day.
University of Maryland-Greenebaum Cancer Center, Baltimore
Fundacion Jimenez Diaz University Hospital, Madrid
Hospital Universitario 12 de Octubre, Madrid
Carolina Bio-Oncology Institute, Pllc, Huntersville
Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
Hospital Clinico Universitario Virgen de La Victoria, Málaga
Emory University, Atlanta
Vanderbilt Medical Center, Nashville
Md Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio
The Angeles Clinic and Research Institute, Los Angeles
Institut Catala Doncologia Ico - Hospital Duran I Reynals Location, Barcelona
Hackensack University Medical Center, Hackensack
Innsbruck University Hospital, Innsbruck
Landeskrankenhaus Salzburg, Salzburg
Cliniques Universitaires Ucl Saint-Luc, Brussels
Institut Jules Bordet, Brussels
Universitair Ziekenhuis Antwerpen (Uza), Edegem
Ghent University Hospital, Ghent
Universitair Ziekenhuis (Uz) Leuven, Leuven
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
University Medical Center Groningen, Groningen
Radboud University Nijmegen Medical Center, Nijmegen
Erasmus Mc Cancer Institute, Rotterdam
University Medical Center Utrecht, Utrecht
Hospital General Universitario Vall D Hebron, Barcelona
Cambridge University Hospitals Nhs Foundation Trust, Cambridge
Guys and St Thomas Nhs Foundation Trust, London
Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London
The Christie Nhs Foundation Trust Uk, Manchester
Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust, Newcastle upon Tyne
The Royal Marsden Nhs Foundation Trust - Chelsea, Sutton
Lead Sponsor
Incyte Corporation
INDUSTRY